Oxurion NV (OXUR.BR)

EUR 0.18

(-3.5%)

Operating Expenses Summary of Oxurion NV

  • Oxurion NV's latest annual operating expenses in 2023 was 12.21 Million EUR , down -46.3% from previous year.
  • Oxurion NV's latest quarterly operating expenses in 2024 Q2 was 2.28 Million EUR , down 0.0% from previous quarter.
  • Oxurion NV reported a annual operating expenses of 22.5 Million EUR in annual operating expenses 2022, down -21.1% from previous year.
  • Oxurion NV reported a annual operating expenses of 28.52 Million EUR in annual operating expenses 2021, down -5.46% from previous year.
  • Oxurion NV reported a quarterly operating expenses of 7.83 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Oxurion NV reported a quarterly operating expenses of 5.06 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Oxurion NV (2023 - 2006)

Historical Annual Operating Expenses of Oxurion NV (2023 - 2006)

Year Operating Expenses Operating Expenses Growth
2023 12.21 Million EUR -46.3%
2022 22.5 Million EUR -21.1%
2021 28.52 Million EUR -5.46%
2020 30.17 Million EUR -18.05%
2019 36.81 Million EUR -9.96%
2018 40.89 Million EUR 111.26%
2017 19.35 Million EUR -68.15%
2016 60.77 Million EUR 31.41%
2015 46.24 Million EUR -24.34%
2014 61.12 Million EUR -24.89%
2013 81.38 Million EUR 89.9%
2012 42.85 Million EUR 58.54%
2011 27.03 Million EUR 33.2%
2010 20.29 Million EUR 7.21%
2009 18.93 Million EUR 23.43%
2008 15.33 Million EUR -17.1%
2007 18.5 Million EUR 48.53%
2006 12.45 Million EUR 0.0%

Peer Operating Expenses Comparison of Oxurion NV

Name Operating Expenses Operating Expenses Difference
ABIONYX Pharma SA 4.17 Million EUR -192.411%
ABIVAX Société Anonyme 127.37 Million EUR 90.411%
Adocia SA 15.62 Million EUR 21.85%
Aelis Farma SA 18.81 Million EUR 35.098%
Biophytis S.A. 14.33 Million EUR 14.784%
Advicenne S.A. 8.21 Million EUR -48.679%
genOway Société anonyme 16.73 Million EUR 27.03%
IntegraGen SA 5.35 Million EUR -128.192%
Medesis Pharma S.A. 1.56 Million EUR -680.661%
Neovacs S.A. 10.34 Million EUR -18.083%
NFL Biosciences SA 4.37 Million EUR -179.218%
Plant Advanced Technologies SA 2.76 Million EUR -341.76%
Quantum Genomics Société Anonyme 1.71 Million EUR -610.957%
Sensorion SA 27.05 Million EUR 54.853%
Theranexus Société Anonyme 3 Million EUR -306.458%
TME Pharma N.V. 5.49 Million EUR -122.194%
Valbiotis SA 9.86 Million EUR -23.761%
TheraVet SA 1.64 Million EUR -642.803%
Valerio Therapeutics Société anonyme 20.32 Million EUR 39.892%
argenx SE 1.34 Billion EUR 99.09%
BioSenic S.A. 7.58 Million EUR -61.071%
Celyad Oncology SA 8.49 Million EUR -43.863%
DBV Technologies S.A. 89.4 Million EUR 86.339%
Galapagos NV 327.98 Million EUR 96.276%
Genfit S.A. 54.8 Million EUR 77.713%
GeNeuro SA 14.35 Million EUR 14.928%
Hyloris Pharmaceuticals SA 17.98 Million EUR 32.095%
Innate Pharma S.A. 64.57 Million EUR 81.084%
Inventiva S.A. 120.18 Million EUR 89.837%
MaaT Pharma SA 21.59 Million EUR 43.448%
MedinCell S.A. 32.92 Million EUR 62.9%
Nanobiotix S.A. 58.92 Million EUR 79.273%
Onward Medical N.V. 20.64 Million EUR 40.838%
Oryzon Genomics S.A. 18.49 Million EUR 33.968%
OSE Immunotherapeutics SA 23.58 Million EUR 48.222%
Pharming Group N.V. 204.24 Million EUR 94.02%
Poxel S.A. 28.76 Million EUR 57.539%
GenSight Biologics S.A. 32.66 Million EUR 62.603%
Transgene SA 31.23 Million EUR 60.891%
Financière de Tubize SA 114.38 Thousand EUR -10577.6%
UCB SA 2.94 Billion EUR 99.585%
Valneva SE 134.92 Million EUR 90.947%
Vivoryon Therapeutics N.V. 24.69 Million EUR 50.535%